- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03026855
Autologous Platelet Rich Plasma (PRP) for the Treatment of Chronic Non-Healing Ulcers
To Demonstrate the Safety and Efficacy of Autologous Platelet Rich Plasma (PRP) for the Treatment of Chronic Non-Healing Ulcers
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Platelet Rich Plasma (PRP) therapy is an innovative treatment that uses body's own cells to relieve pain and promote accelerated healing of Non-healing Foot Ulcer /Wound. The body's response to any tissue injury is to deliver platelets, which play an instrumental role in the normal healing process by secreting growth factors and attracting stem cells-critical components of the healing cascade.
Any wound or ulcer on skin that has been present for 4-5 weeks duration, without healing is called a non-healing ulcer. Non-healing ulcers include venous, arterial, diabetic, pressure and traumatic ulcers. Cellular therapies using Autologous Platelet Rich Plasma provides new options for wound healing. The efficacy of the treatment has been proven in surgical applications, in the treatment of severe burns and in transplantation of cells and tissues.
Local application of a solution of plasma enriched in platelets derived from the patient's blood intends to trigger the healing process in non-responsive chronic wound, increase the wound repair rate and reduce pain. PRP is a good option for non-healing wounds because it utilizes the body's natural healing processes to jump-start wound healing. Plasma which contains very valuable growth factors is separated from other blood components utilizing a point of care technology based on density gradient centrifugation. The platelet rich plasma is harvested and then activated by a mixture of human thrombin and calcium chloride for initiating the healing cascade followed by PRP injection directly into the ulcer/wound periphery or spread over a wound in the form of a PRP gel.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Delhi, Indien, 110025
- Fortis Escorts Heart Institute and Research Centre
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male or Female 18 to 85 years of age
- Chronic or Non-healing ulcer of any etiology (venous, pressure, arterial or diabetic foot ulcer) which is at least 4 weeks old
- Index foot ulcer located on the plantar, medial or lateral aspect of the foot (including all toe surfaces)
- Wound area (length x width) measurement must be between 0.5 cm^2 and 10 cm^2, inclusive
- If more than one non-healing ulcers is present, the largest wound will be selected
- Index ulcer must be clinically non-infected
- Full-thickness ulcer without exposure of bone, muscle, ligament or tendon
- Written informed consent must be obtained from either the patient or the patients legally acceptable representative prior to enrollment
Exclusion Criteria:
- Patients with known sensitivity to components of the PRP kit (calcium chloride, thrombin, acid citrate dextrose solution A (ACD-A))
- Smokers and individuals with systemic disease or history of anticoagulant, immuno-suppressive or antibiotic therapy in the last 3 months
- Platelet count < 105 x 10^3/ uL (according to CBC)
- Hemoglobin level < 10 g/dL (according to CBC)
- Wound is clinically infected
- Presence of platelet dysfunction syndrome or critical thrombocytopenia
- Bleeding disorders, collagen vascular disease or severe cardiovascular disorder
- Any malignancy other than non-melanoma skin cancer
- Patient is currently receiving or has received radiation or chemotherapy within 3 months prior to treatment
- If female, patient is pregnant, nursing or plans to become pregnant during the duration of the study
- Subject has inadequate venous access for blood draw required for PRP preparation
- Any chronic condition requiring the use of systemic corticosteroids 30 days prior to study entry and anytime during the course of the study
- Subject is on dialysis or has uncontrolled sugar levels
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Autologous PRP Gel and PRP Injection
Autologous PRP will be prepared using an advanced rapid point-of-care technology, the Res-Q™ 60 PRP system at the patient's bed side.
The Activator solution for PRP gel will be prepared by combining human thrombin (500 IU/ml) with 1% Calcium Chloride.
|
Autologous PRP prepared using the Res-Q™ 60 PRP system from patient's whole blood, will be injected subcutaneously around the periphery of the wound/ulcer. Based on the wound size and area, autologous platelet gel obtained by spraying simultaneously equal volumes of PRP and activator solution (thrombin with calcium chloride) will be applied topically over the ulcer or wound. Single dose of PRP injections and application of PRP gel will be administered, only on the day of treatment. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Wound/ Ulcers Healed
Tidsramme: 24 weeks
|
The number of wound/ ulcers healed will be assessed by visual inspection of reduction in wound size at 24 weeks post PRP therapy
|
24 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to Ulcer Healing
Tidsramme: 24 weeks
|
The average time taken for the ulcers to heal post PRP administration
|
24 weeks
|
|
Reduction in Pain using VAS pain score
Tidsramme: 24 weeks
|
Improvement in Pain and discomfort following PRP therapy
|
24 weeks
|
|
Changes in Quality of Life using the SF-36 Questionnaire
Tidsramme: 24 weeks
|
Improvement in Quality of Life of the patients following PRP therapy
|
24 weeks
|
|
Number of participants with treatment-related Adverse Events
Tidsramme: 24 weeks
|
Safety of the treatment will be assessed by measuring the number of treatment related adverse events and adverse reactions during the follow-up period
|
24 weeks
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Dr. Suhail N Bukhari, MBBS, DNB, Fortis Escorts Heart Institute and Research Centre
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- TPRX/PRP/NHU/141005
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kronisk sår
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekrutteringRefractory Chronic Graft Versus Host Disease (cGVHD)Belgien
-
Bahria UniversityIslamabad Medical and Dental CollegeAktiv, ikke rekrutterendeAlveolær knogletab Associated Chronic PeriodontitisPakistan
-
West China HospitalIkke rekrutterer endnuPTLD'er | CAEBV (Chronic Active Epstein-Barr Virus Infection) SyndromKina
-
Beijing Friendship HospitalIkke rekrutterer endnuEBV | Hæmofagocytiske lymfohistiocytoser | CAEBV (Chronic Active Epstein-Barr Virus Infection) SyndromKina
-
Novartis PharmaceuticalsLedigPrimær myelofibrose (PMF) | Polycytæmi Vera (PV) | Post polycytæmi myelofibrose (PPV MF) | Trombocytæmi myelofibrose (PET-MF) | Alvorlig/meget svær COVID-19 sygdom | Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD) | Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)
Kliniske forsøg med Autologous PRP Gel and PRP Injection
-
Arteriocyte, Inc.AfsluttetDiabetiske fodsår | Tryksår | Venøse sårForenede Stater
-
Yasmine Ahmed Abd El-Maguid El-HadidyUkendtAtrofisk acne arEgypten
-
Tampere UniversityAfsluttet
-
Alexandria UniversityAfsluttetEndodontisk sygdomEgypten
-
Mansoura UniversityAfsluttet
-
CytomedixCTI Clinical Trial and Consulting ServicesAfsluttetDiabetiske fodsår | Sår | Tryksår | BensårForenede Stater
-
Arteriocyte, Inc.Department of Health and Human ServicesUkendtAkutte dybe termiske forbrændinger af delvis tykkelseForenede Stater
-
University of OxfordNational Institute for Health Research, United KingdomAfsluttetAchilles-senerupturDet Forenede Kongerige
-
Mashhad University of Medical SciencesAristotle University Of ThessalonikiAktiv, ikke rekrutterende
-
McMaster UniversityArthrex, Inc.; The Physicians' Services Incorporated Foundation; Radiological...AfsluttetLateral epikondylitis (tennisalbue)Canada, Forenede Stater